Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
WBBM Radio Chicago on MSN56m
FDA approves new treatment for schizophreniaWith Thursday approval from the U.S. Food and Drug Administration for Cobenfy, adults living with schizophrenia will have ...
The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the ...
In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...
The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...
The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.
Bristol Myers Squibb (BMY) is up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback